iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) Sets New 12-Month High – Here’s What Happened

iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE)’s share price hit a new 52-week high during trading on Tuesday . The company traded as high as $102.57 and last traded at $102.57, with a volume of 1060 shares. The stock had previously closed at $100.25.

iShares U.S. Pharmaceuticals ETF Trading Up 2.6%

The business’s 50-day moving average price is $91.96 and its 200-day moving average price is $88.89. The stock has a market cap of $1.19 billion, a PE ratio of 17.75 and a beta of 0.49.

Institutional Trading of iShares U.S. Pharmaceuticals ETF

Institutional investors have recently made changes to their positions in the business. Foundations Investment Advisors LLC acquired a new position in iShares U.S. Pharmaceuticals ETF during the 4th quarter valued at about $54,513,000. Bank of America Corp DE raised its position in shares of iShares U.S. Pharmaceuticals ETF by 2.8% in the 1st quarter. Bank of America Corp DE now owns 456,606 shares of the company’s stock valued at $39,579,000 after purchasing an additional 12,565 shares during the last quarter. JPMorgan Chase & Co. grew its position in iShares U.S. Pharmaceuticals ETF by 89.4% during the 4th quarter. JPMorgan Chase & Co. now owns 212,805 shares of the company’s stock worth $18,052,000 after purchasing an additional 100,426 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in iShares U.S. Pharmaceuticals ETF during the 2nd quarter valued at approximately $13,108,000. Finally, Royal Bank of Canada lifted its stake in shares of iShares U.S. Pharmaceuticals ETF by 51.9% during the fourth quarter. Royal Bank of Canada now owns 156,973 shares of the company’s stock worth $13,315,000 after buying an additional 53,661 shares during the period.

About iShares U.S. Pharmaceuticals ETF

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.